Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study

European Journal of Endocrinology

Volumn 169, Issue 6, 2013, Pages 795-804

  Norenstedt, Sophie ^a,b   Pernow, Ylva ^a,b   Brismar, Kerstin ^a,b   Sääf, Maria ^a,b   Ekip, Ayla ^a   Granath, Fredrik ^a   Zedenius, Jan ^a,b   Nilsson, Inga Lena ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CARBONATE; CALCIUM CHANNEL BLOCKING AGENT; COLECALCIFEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTROGEN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; PARATHYROID HORMONE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; STEROID;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BONE MINERAL; CARDIOMETABOLIC RISK; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; POSTOPERATIVE PERIOD; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SWEDEN; SYSTOLIC BLOOD PRESSURE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; BLOOD; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; DEFICIENCY; DRUG ADMINISTRATION; DRUG EFFECTS; HYPERPARATHYROIDISM, PRIMARY; MIDDLE AGED; PATHOPHYSIOLOGY; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; AGED; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; BODY COMPOSITION; CALCIUM CARBONATE; CHOLECALCIFEROL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; INSULIN RESISTANCE; MALE; MIDDLE AGED; PARATHYROID HORMONE; PARATHYROIDECTOMY; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TREATMENT OUTCOME;

EID: 84888244925     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0547     Document Type: Article

References (44)

1. Hedback GM & Oden AS. Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism. Journal of Internal Medicine 2002 251 476-483. (doi:10.1046/j.1365-2796.2002. 00984.x)
2. Nilsson IL, Yin L, Lundgren E, Rastad J & Ekbom A. Clinical presentation of primary hyperparathyroidism in Europe - nationwide cohort analysis on mortality from nonmalignant causes. Journal of Bone and Mineral Research 2002 17 (Suppl 2) N68-N74.
3. Farahnak P, Larfars G, Sten-Linder M & Nilsson IL. Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers. Journal of Clinical Endocrinology and Metabolism 2011 96 2112-2118. (doi:10.1210/jc.2011-0238)
4. Walker MD, Fleischer JB, Di Tullio MR, Homma S, Rundek T, Stein EM, Zhang C, Taggart T, McMahon DJ & Silverberg SJ. Cardiac structure and diastolic function in mild primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2010 95 2172-2179. (doi:10.1210/jc.2009-2072)
5. Lundgren E, Ljunghall S, Akerstrom G, Hetta J, Mallmin H & Rastad J. Case-control study on symptoms and signs of "asymptomatic" primary hyperparathyroidism. Surgery 1998 124 980-985 discussion 985-986. (doi:10.1016/S0039-6060 (98) 70038-8)
6. Hagstrom E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundstrom J, Melhus H, Held C, Lind L, Michaelsson K et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009 119 2765-2771. (doi:10.1161/CIRCULATIONAHA.108.808733)
7. Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Shaw JE, Zimmet PZ, Sikaris K, Ebeling PR & Daly RM. Low serum 25-hydroxyvitamin D is associated with increased risk of the development of the metabolic syndrome at five years: results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab). Journal of Clinical Endocrinology and Metabolism 2012 97 1953-1961. (doi:10.1210/jc. 2011-3187)
8. Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Shaw JE, Zimmet PZ, Sikaris K, Grantham N, Ebeling PR & Daly RM. Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5 years: results from a national, population-based prospective study (the Australian Diabetes, Obesity and Lifestyle study). Diabetes Care 2011 34 1133-1138. (doi:10.2337/dc10-2167)
9. Burgaz A, Orsini N, Larsson SC & Wolk A. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. Journal of Hypertension 2011 29 636-645. (doi:10.1097/HJH. 0b013e32834320f9)
10. Anderson JL, May HT, Horne BD, Bair TL, Hall NL, Carlquist JF, Lappe DL & Muhlestein JB. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. American Journal of Cardiology 2010 106 963-968. (doi:10.1016/j.amjcard.2010. 05.027)
11. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB & Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. New England Journal of Medicine 2001 345 1291-1297. (doi:10.1056/NEJMoa003417)
12. Lemne C & Brismar K. Insulin-like growth factor binding protein-1 as a marker of the metabolic syndrome - a study in borderline hypertension. Blood Pressure 1998 7 89-95.
13. Brismar K, Gutniak M, Povoa G, Werner S & Hall K. Insulin regulates the 35 kDa IGF binding protein in patients with diabetes mellitus. Journal of Endocrinological Investigation 1988 11 599-602.
14. Heald AH, Cruickshank JK, Riste LK, Cade JE, Anderson S, Greenhalgh A, Sampayo J, Taylor W, Fraser W, White A et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001 44 333-339. (doi:10.1007/s001250051623)
15. Unden AL, Elofsson S & Brismar K. Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study. Clinical Endocrinology 2005 63 94-102. (doi:10.1111/j.1365-2265. 2005.02306.x)
16. Petersson U, Ostgren CJ, Brudin L, Brismar K & Nilsson PM. Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): the Soderakra Cardiovascular Risk Factor Study. Diabetes & Metabolism 2009 35 198-205. (doi:10.1016/j.diabet.2008.11.003)
17. Hellenius ML, Brismar KE, Berglund BH & de Faire UH. Effects on glucose tolerance, insulin secretion, insulin-like growth factor 1 and its binding protein, IGFBP-1, in a randomized controlled diet and exercise study in healthy, middle-aged men. Journal of Internal Medicine 1995 238 121-130. (doi:10.1111/j.1365-2796.1995. tb00909.x)
18. Valcour A, Blocki F, Hawkins DM & Rao SD. Effects of age and serum 25-OH-vitamin D on serum parathyroid hormone levels. Journal of Clinical Endocrinology and Metabolism 2012 97 3989-3995. (doi:10.1210/jc.2012-2276)
19. Cockcroft DW & Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 31-41. (doi:10.1159/000180580)
20. Bilezikian JP, Khan AA & Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. Journal of Clinical Endocrinology and Metabolism 2009 94 335-339. (doi:10.1210/jc.2008-1763)
21. Povoa G, Roovete A & Hall K. Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinologica 1984 107 563-570.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419. (doi:10. 1007/BF00280883)
23. Boudou P, Ibrahim F, Cormier C, Sarfati E & Souberbielle JC. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. Journal of Endocrinological Investigation 2006 29 511-515.
24. Nordenstrom E, Westerdahl J & Bergenfelz A. Long-term follow-up of patients with elevated PTH levels following successful exploration for primary hyperparathyroidism. World Journal of Surgery 2004 28 570-575.
25. Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz JP, Liu H, Lane MA, Mullan RJ, Hazem A et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism 2011 96 1931-1942. (doi:10.1210/jc.2011-0398)
26. Leu M & Giovannucci E. Vitamin D: epidemiology of cardiovascular risks and events. Best Practice & Research. Clinical Endocrinology & Metabolism 2011 25 633-646. (doi:10.1016/j. beem.2011.04.001)
27. Anderson JL, Vanwoerkom RC, Horne BD, Bair TL, May HT, Lappe DL & Muhlestein JB. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? American Heart Journal 2011 162 331-339. (doi:10.1016/j.ahj.2011.05.005)
28. Rejnmark L, Avenell A, Masud T, Anderson F, Meyer HE, Sanders KM, Salovaara K, Cooper C, Smith HE, Jacobs ET et al. Vitamin D with calcium reduces mortality: patient level pooled analysis of 70, 528 patients from eight major vitamin D trials. Journal of Clinical Endocrinology and Metabolism 2012 97 2670-2681. (doi:10.1210/jc.2011-3328)
29. Hagstrom E, Hellman P, Lundgren E, Lind L & Arnlov J. Serum calcium is independently associated with insulin sensitivity measured with euglycaemic-hyperinsulinaemic clamp in a community-based cohort. Diabetologia 2007 50 317-324. (doi:10.1007/s00125-006-0532-9)
30. Ayturk S, Gursoy A, Bascil Tutuncu N, Ertugrul DT & Guvener Demirag N. Changes in insulin sensitivity and glucose and bone metabolism over time in patients with asymptomatic primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2006 91 4260-4263. (doi:10.1210/jc.2005-2825)
31. Bollerslev J, Rosen T, Mollerup CL, Nordenstrom J, Baranowski M, Franco C, Pernow Y, Isaksen GA, Godang K, Ueland T et al. Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2009 94 2255-2261. (doi:10.1210/jc.2008- 2742)
32. Rubin MR & Silverberg SJ. Glucose intolerance and primary hyperparathyroidism: an unresolved relationship. Endocrine 2012 42 231-233. (doi:10.1007/s12020-012-9674-3)
33. Nilsson IL, Rastad J, Johansson K & Lind L. Endothelial vasodilatory function and blood pressure response to local and systemic hypercalcemia. Surgery 2001 130 986-990. (doi:10. 1067/msy.2001.118368)
34. Farahnak P, Ring M, Caidahl K, Farnebo LO, Eriksson MJ & Nilsson IL. Cardiac function in mild primary hyperparathyroidism and the outcome after parathyroidectomy. European Journal of Endocrinology 2010 163 461-467. (doi:10.1530/EJE-10-0201)
35. Kannel WB, Vasan RS & Levy D. Is the relation of systolic blood pressure to risk of cardiovascular disease continuous and graded, or are there critical values? Hypertension 2003 42 453-456. (doi:10.1161/01. HYP.0000093382.69464. C4)
36. Staessen JA, Asmar R, De Buyzere M, Imai Y, Parati G, Shimada K, Stergiou G, Redon J & Verdecchia P. Task force II: blood pressure measurement and cardiovascular outcome. Blood Pressure Monitoring 2001 6 355-370. (doi:10.1097/00126097-200112000-00016)
37. Luigi P, Chiara FM, Laura Z, Cristiano M, Giuseppina C, Luciano C, Giuseppe P, Sabrina C, Susanna S, Antonio C et al. Arterial hypertension, metabolic syndrome and subclinical cardiovascular organ damage in patients with asymptomatic primary hyperparathyroidism before and after parathyroidectomy: preliminary results. International Journal of Endocrinology 2012 2012 408295. (doi:10.1155/2012/408295)
38. Feldstein CA, Akopian M, Pietrobelli D, Olivieri A & Garrido D. Long-term effects of parathyroidectomy on hypertension prevalence and circadian blood pressure profile in primary hyperparathyroidism. Clinical and Experimental Hypertension 2010 32 154-158. (doi:10.3109/10641960903254471)
39. Letizia C, Ferrari P, Cotesta D, Caliumi C, Cianci R, Cerci S, Petramala L, Celi M, Minisola S, D'Erasmo E et al. Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. Journal of Human Hypertension 2005 19 901-906. (doi:10.1038/sj.jhh.1001907)
40. Rydberg E, Birgander M, Bondeson AG, Bondeson L & Willenheimer R. Effect of successful parathyroidectomy on 24-hour ambulatory blood pressure in patients with primary hyperparathyroidism. International Journal of Cardiology 2010 142 15-21. (doi:10.1016/j.ijcard.2008.12.027)
41. Nilsson IL, Aberg J, Rastad J & Lind L. Circadian cardiac autonomic nerve dysfunction in primary hyperparathyroidism improves after parathyroidectomy. Surgery 2003 134 1013-1019 discussion 1019. (doi:10.1016/j.surg.2003.07.017)
42. Nilsson IL, Aberg J, Rastad J & Lind L. Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. Surgery 1999 126 1049-1055. (doi:10. 1067/msy.2099.101422)
43. Kosch M, Hausberg M, Vormbrock K, Kisters K, Gabriels G, Rahn KH & Barenbrock M. Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy. Cardiovascular Research 2000 47 813-818. (doi:10.1016/S0008-6363 (00) 00130-9)
44. Fallo F, Camporese G, Capitelli E, Andreozzi GM, Mantero F & Lumachi F. Ultrasound evaluation of carotid artery in primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism 2003 88 2096-2099. (doi:10.1210/jc.2002-021837)